Home
Learn More
Features & Pricing
Success Stories
Contact Us
Search Archives
Journalists
Submit Release
February 9, 2010
 
Industry Categories  
News by Country  
News by MSA  
Today's News  
Browse by Day  
PR Trackbacks™  
Featured Videos  
ViewNews™  
eBook Digests  
RSS  
PRWeb, a leader in online news and press release distribution, has been used by more than 40,000 organizations of all sizes to increase the visibility of their news, improve their search engine rankings and drive traffic to their Websites.
 
Close Move
All Press Releases for November 1, 2006 Subscribe to this News Feed      
 

Experience Enduring Beauty with the Permanent Wrinkle Solution

Dr. Jeffrey Adelglass, M.D., F.A.C.S. of SKINTASTIC™ in Plano will soon be among the first physicians in Texas to offer a new, unique, and permanent solution to filler re-absorption: ArteFill® from Artes Medical. Long-awaited ArteFill® is finally FDA-approved in the U.S., for the correction of nasolabial folds, or smile lines. Artefill® is the first and only non-resorbable aesthetic injectable implant of its kind approved for use in the U.S.

Plano, Texas (PRWEB / PRWEB) November 1, 2006 -- Dr. Jeffrey Adelglass, M.D., F.A.C.S. of SKINTASTIC™ in Plano will soon be among the first physicians in Texas to offer a new, unique, and permanent solution to filler re-absorption: ArteFill® from Artes Medical. Long-awaited ArteFill® is finally FDA-approved in the U.S., for the correction of nasolabial folds, or smile lines. Artefill® is the first and only non-resorbable aesthetic injectable implant of its kind approved for use in the U.S.

If you know anything about what's going on in the world of facial plastic surgery and medical aesthetics, you probably know that cosmetic injectable dermal fillers are all the rage. As you age, your body's ability to produce collagen (a natural component of your skin that keeps your face smooth and wrinkle free) gradually declines. Dermal fillers were developed to fill in the 'tell-tale' wrinkles, creases, and folds that occur with aging and the slowdown of collagen production.

There are a variety of dermal filler options available, but most are temporary (lasting 6-9 months), so repeated injections are necessary to maintain results. These formulas were developed to be accepted by the body with a minimal chance of allergic reaction; the downside being that the body gradually absorbs these fillers as if they were a nourishing snack. A more permanent alternative, logically, then would be use of a synthetic filler that does not biodegrade over time. A suitable synthetic filler should have a very low risk of allergic reaction and should not migrate outside of the treatment area.

The permanent solution has finally arrived.

Artefill® consists of a combination of bovine collagen, 0.3% lidocaine (to lessen discomfort associated with injection), and smooth synthetic polymethylmethacrylate (PMMA) microspheres. PMMA is a very common synthetic implant material used in medicine. Three to six months following Artefill injection, the bovine collagen is gradually absorbed, replaced by the body's own newly-created collagen which forms to encapsulate the microspheres in a natural biologic process. ArteFill®'s microspheres provide a permanent support structure beneath the skin to fill out wrinkles and to prevent further wrinkling in the treated areas. The microspheres do not migrate nor are they degraded by the body. Therefore, they remain surrounded by your natural collagen, providing permanent volume to keep your skin smooth and wrinkle-free in the areas you were treated, presumably for the rest of your life.

Due to the fact that a certain percentage of people are allergic to bovine collagen or lidocaine, a preliminary ArteFill® allergy test is required a month before injection. There are no known allergies to the synthetic (PMMA) microsphere material. Artecoll, a predecessor of Artefill® has been administered to over 200,000 patients in over 50 countries over the past 10 years. ArteColl has been in cosmetic use since the late eighties (outside the U.S.), longer than any other synthetic filler.

Of course, as Artefill® is a permanent filler, the results are permanent. Artefill® should only be injected by a qualified, highly-trained physician injector. Experience counts. The optimal candidate is someone who has received filler treatments before and is sure that they're ready for a permanent change. Also, ArteFill® can be used for men or women of all ages, but it is not advised for elderly patients with thin, flaccid skin.

North Dallas/Plano physician and surgeon Jeffrey Adelglass currently serves on the scientific advisory boards of Artes Medical, and many other U.S. cosmetic filler companies. Further, SKINTASTIC™ has been designated as a BOTOX® Cosmetic National Education Center, which means Dr. Adelglass was chosen by Allergan, the makers of BOTOX® Cosmetic, to instruct other physicians in his medical technique so that they can achieve safe, effective and consistent results. BOTOX® Cosmetic can be injected on the same day as ArteFill® permanent filler, for a BOTOX® Cosmetic and ArteFill® Facelift.

If you are in Texas and would like to receive a skin test and complimentary consultation to see if you are a candidate for Artefill® permanent filler, contact SKINTASTIC™ at 972-620-FACE (3223). Individuals interested in undergoing Artefill® skin testing will be contacted for scheduling in the order that their inquiry was received, as soon as SKINTASTIC™ receives skin tests from the manufacturer.

Visit the SKINTASTIC™ website at www.skintastic.com for general ArteFill® information as it becomes available. Questions regarding ArteFill® permanent dermal filler availability at SKINTASTIC™ should be referred to Dr. Jeffrey Adelglass directly, at (972) 620-3223, or by email.

Dr. Adelglass is a facial plastic surgeon and clinical researcher, and is founder and Medical Director of SKINTASTIC™ Medical and Surgical Skin Rejuvenation Center, a North Dallas area medical spa that offers a wide range of cosmetic corrections from facial cosmetic surgery (facelifts) to Botox® Cosmetic, fillers such as Restylane®, Juvederm®, Sculptra® and Radiesse®, lasers, Mesotherapy, Fotofacial, GentleLift Contour Threading face lifts, Thermage™, and Fraxel™. Dr. Adelglass is periodically called upon by local and national media and scientific groups to inform the public on topics regarding clinical research, and recent advances in medical and surgical aesthetic correction. Please feel free to contact our office at 972-620-3223 with any questions for Dr. Adelglass, or to schedule a personal consultation with him. In addition, he may be available to speak on a number of subjects relating to surgical and non-surgical aesthetic enhancements, at your next civic, community or private event.

###

Post Comment:
Trackback URL: http://ca.prweb.com/pingpr.php/SGFsZi1GYWx1LUhhbGYtQ291cC1NYWduLVplcm8=

See the original story at: http://www.prweb.com/releases/2006/11/prweb468437.htm

Trackbacks/Comments Received

Thermage Essentials » Blog Archive » Experience Enduring Beauty with the Permanent Wrinkle Solution from thermage-essentials.com on Nov 2, 2006   Preview Open

Post Comment:
Trackback URL: http://ca.prweb.com/pingpr.php/SGFsZi1GYWx1LUhhbGYtQ291cC1NYWduLVplcm8=

Bookmark -  Del.icio.us | Furl | Technorati | Ask | Y!MyWeb | Propeller | Live Bookmarks | Newsvine | TailRank | Reddit | Slashdot | Digg | Stumbleupon | Google Bookmarks | Sphere | Blink It | Spurl


OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
Download Podcast MP3
Download Podcast iTunes
BlogThis
ShareIt

Share The News

Submit this press release easily to any of these major bookmarking and social media sites.

CONTACT INFORMATION
Jeffrey Adelglass
SKINTASTIC
972-620-3223
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your login.

ABOUT PRESS RELEASES
 

 

© Copyright 1997-2010, Vocus PRW Holdings, LLC.
Vocus, PRWeb, PRWeb UK and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.